Newsletter | October 21, 2021

10.21.21 -- Ensure Clinical Success With Advanced Characterization Of Immune Cell Therapies From The Start

The Importance Of Subtype Ratio For CAR-T Therapy Efficacy

Development of nonviral and allogeneic CAR-based therapies that can effectively target solid tumors are at the forefront of cancer treatment innovation. In this webinar, Dr. Devon Shedlock of Poseida Therapeutics shares the company's approach to manufacturing allogeneic CAR-T therapy and discusses the importance of stemness for effectiveness in the clinic.

Watch Now

Automation Strategies To Enable Characterization Of CAR-T Cell Therapies

CAR-T therapies have shown tremendous clinical potential. However, manufacturing remains challenging due to the lack of control and automation as well as process and cell product characterization during process development and manufacturing stages. In this edition of Experts’ Insights in Advanced Therapies, Dr. Qasim Rafiq, of UCL, shares insights from his development of an automated CAR-T expansion process.

Read Q&A Now

What Will It Take To Realize The Promise And Potential Of Immune Cell Therapies?

Remarkable progress is being made in the treatment of cancer with CAR-T therapies, but their manufacturing remains costly. Learn about the factors contributing to the high cost of goods and explore how to enable more efficient and cost-effective production.

Read Full Article


Additional Resources
A Differentiated Approach To Allogeneic Cell Therapy Manufacturing

Celyad Oncology CEO Filippo Petti digs in on differentiating his company’s approach to developing and manufacturing allogeneic cell therapies for several oncology indications, including the company's technology platform and scale-up strategies in Celyad’s Belgium-based clinical manufacturing facility.  

Scaling Cell And Gene Therapy Manufacturing Operations

Manufacturing autologous cell therapy products faces few key complications, which is typically why CAR-T manufacturing runs at two or three sigma operations.